A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-beta 1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Tonogenchoncel-L (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Kolon TissueGene; TissueGene
- 16 Mar 2018 According to a Kolon TissueGene media release, TissueGene changed its name to Kolon TissueGene.
- 11 May 2015 According to a TissueGene media release, data from this study were presented at the 12th World Congress of the International Cartilage Repair Society (ICRS) 2015.
- 11 May 2015 According to a TissueGene media release, data from this study were presented at the 18th meeting of the American Society of Gene & Cell Therapy (ASGCT) 2015.